Studies on aromatase inhibitors. IV. Synthesis and biological evaluation of N,N-disubstituted-5-aminopyrimidine derivatives. 1997

M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
Medicinal Chemistry Research II, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.

In order to study the potency of the 5-aminopyrimidine skeleton as an aromatase inhibitor, we synthesized various N,N-disubstituted-5-aminopyrimidine derivatives and evaluated their aromatase-inhibitory activity (in vitro) and their inhibitory activity on pregnant mare serum gonadotropin (PMSG)-induced estrogen synthesis (in vivo). Compounds with the fluoro-substituted benzyl group showed potent aromatase inhibition. Among them, 5-[(4-cyanophenyl)(3,5-difluorobenzyl)amino]pyrimidine (5w, YM553) was a highly potent compound with an IC50 value of 0.038 nM for aromatase from human placenta. Its inhibitory effect was approximately four times greater than that of YM511. In addition, YM553 was a weak inhibitor of other enzymes involved in steroid hormone synthesis. These results indicate that YM553, as well as YM511 (a 4-amino-4H-1,2,4-triazole derivative), is a promising agent for the treatment of estrogen-dependent diseases.

UI MeSH Term Description Entries
D008297 Male Males
D008861 Microsomes Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) Microsome
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002627 Chemistry, Physical The study of CHEMICAL PHENOMENA and processes in terms of the underlying PHYSICAL PHENOMENA and processes. Physical Chemistry,Chemistries, Physical,Physical Chemistries
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females
D006064 Gonadotropins, Equine Gonadotropins secreted by the pituitary or the placenta in horses. This term generally refers to the gonadotropins found in the pregnant mare serum, a rich source of equine CHORIONIC GONADOTROPIN; LUTEINIZING HORMONE; and FOLLICLE STIMULATING HORMONE. Unlike that in humans, the equine LUTEINIZING HORMONE, BETA SUBUNIT is identical to the equine choronic gonadotropin, beta. Equine gonadotropins prepared from pregnant mare serum are used in reproductive studies. Pregnant Mare Serum Gonadotropins,PMS Gonadotropins,PMSG (Gonadotropins),Equine Gonadotropins,Gonadotropins, PMS
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
August 2016, European journal of medicinal chemistry,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
September 2018, Bioorganic chemistry,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
November 2023, Bioorganic & medicinal chemistry letters,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
January 1976, Polish journal of pharmacology and pharmacy,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
January 2021, Medicinal chemistry (Shariqah (United Arab Emirates)),
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
November 2017, Molecules (Basel, Switzerland),
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
December 2013, Journal of enzyme inhibition and medicinal chemistry,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
June 1985, Journal of medicinal chemistry,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
January 2015, Chemical & pharmaceutical bulletin,
M Okada, and T Yoden, and E Kawaminami, and Y Shimada, and M Kudoh, and Y Isomura
April 2022, Bioorganic chemistry,
Copied contents to your clipboard!